Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
The stock in this headline is Ginkgo Bioworks Holdings, Inc. (NYSE: DNA). A Motley Fool article dated October 5, 2026 says Ginkgo partnered with Eli Lilly on AI drug discovery and that its shares then doubled. The deal is a reported services collaboration. Ginkgo’s data-generation business, Ginkgo Datapoints, is being brought into Lilly TuneLab, Lilly’s AI/ML drug-discovery platform. It is not an acquisition, and no equity investment has been established.
What the Lilly deal is
A September 16 report, a republished press release, says Ginkgo Datapoints entered an agreement with Lilly TuneLab. The agreement brings Ginkgo’s biological data-generation services into the network around TuneLab, which Lilly describes as a collaborative AI/ML platform for drug discovery.
The logic is simple. AI models for drug discovery depend on good biological data. Ginkgo sells that kind of lab-generated data. According to a July 2026 SEC-filed company announcement, Ginkgo offers autonomous laboratories and cloud-lab contract research services through Datapoints and Solutions.
Recommended Free Tools
What is not known
- Financial terms, exclusivity, and milestone payments were not stated in the reports reviewed.
- Research targets and the expected revenue contribution to Ginkgo were not stated.
- No drug candidate or clinical result from the collaboration has been reported.
- No attributable executive quote about the TuneLab collaboration appeared in the September report.
- No primary Lilly or Ginkgo filing with full deal terms was available, so the details rest on the press-release republication and the financial-news coverage.
Did the shares really double?
The “doubled” claim comes from the October 5 Motley Fool article. The sources reviewed give no dated prices or measurement window, so the return cannot be independently reconstructed here. Check the start and end dates against a price chart before relying on the figure.
#1 Best Overall
The article ties the move to investor reaction to the partnership. That is a timing association, not proof of cause. A stock that doubles from a low base can reflect other factors too, such as sentiment, short covering, or trading volume.
Who Ginkgo is
Ginkgo’s annual report filed with the SEC describes two operating businesses:
Rank #2
- Cell engineering: biological R&D services.
- Biosecurity: services for identifying, monitoring, preventing, mitigating, and responding to biological threats.
It has pursued other partnerships as well. Solvay, for example, announced a collaboration focused initially on sustainable biopolymers and said it would acquire a Ginkgo laboratory in Cambridge, Massachusetts. That deal is unrelated to Lilly and says nothing about TuneLab. It does show that partnering is part of Ginkgo’s model.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchPC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Is Ginkgo profitable?
No. Ginkgo’s 2025 10-K reports the following:
| Item (fiscal 2025 unless noted) | Figure |
|---|---|
| Cell engineering revenue | $132.7 million (down from $174.0 million in 2024) |
| Biosecurity revenue | $37.4 million (down from $53.1 million in 2024) |
| Net loss | $312.763 million |
| Cash and cash equivalents, Dec. 31, 2025 | $167.2 million |
| Marketable securities, Dec. 31, 2025 | $255.4 million |
The filing attributes the revenue declines to contract-specific and government-program factors. These are year-end 2025 balances, not October 2026 figures. A partnership with a major pharma name can change sentiment quickly. It does not by itself show that the business is profitable.
Rank #3
How to judge whether the deal matters
Use these questions as new information appears:
- What is supplied? The service role is the one thing the sources clearly establish: biological data generation.
- Is the platform open or exclusive? A shared network may bring in many providers and limit Ginkgo’s share of the work.
- What are the economics? Look for disclosed payments, milestones, and how revenue is recognized.
- Does it reach validated results? Moving from discovery to preclinical or clinical evidence is what separates a data contract from a drug program.
- Can Ginkgo fund delivery? With a 2025 net loss of more than $300 million, the core business has to support the work sustainably.
Not to be confused with
Other Lilly-related small-cap news circulated around the same time, including an unrelated AtaiBeckley acquisition story. The “doubled after a Lilly deal” article concerns Ginkgo and TuneLab only.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.The Bottom Line
Ginkgo’s Lilly TuneLab agreement is a reported data-services partnership with undisclosed terms. The doubling is one article’s claim, and Ginkgo remains loss-making on its latest annual filing. Treat the deal as an early signal, not proof of financial results. This is general information, not investment advice.
Quick Recap
Best Value
- Comes with secure packaging
- Easy to read text
- It can be a gift option
Rank #4
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →
